-
Nuplazid Does Not Lead to Different Mortality Risk Compared to Other Antipsychotics
Treatment with Nuplazid (pimavanserin) does not lead to a different mortality risk compared to the antipsychotic medication Seroquel (quetiapine), or to combination treatment with both medications, in patients with Parkinson’s psychosis, according to results from a large study.
Read a summary of the study and its findings here.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.